Uncategorized

Cadena Research empowers radiopharmaceutical innovators by delivering tailored solutions that accelerate the path to clinical translation. Hamilton, Ontario – September 29, 2025 – CPDC, a global leader in the development and commercialization of radiopharmaceuticals, is proud to announce the launch of Cadena Research, a new preclinical contract research organization (CRO) offering specialized support for early-stage drug … Read more

HAMILTON, ON, June 12, 2025 – CPDC, a global leader in the development and commercialization of radiopharmaceuticals, today announced a $650,000 seed investment in RadioSyn Ltd., a Hamilton-based startup company developing a miniaturized automated radiopharmaceutical synthesis device. The shielded synthesizer uses disposable microfluidic chips to perform end-to-end chemical and radiochemical reactions to synthesize radiopharmaceuticals at … Read more

HAMILTON, ON, June 12, 2025 – CPDC and Lab2Market (L2M) today announced the L2M Discover Radiopharma program, a groundbreaking initiative to cultivate entrepreneurial skills among Canadian researchers in the radiopharmaceutical sector. Beginning on September 16, 2025, the 10-week virtual training program will equip students and faculty with the foundational tools necessary to embark on their … Read more

CQDM and the Centre for Probe Development and Commercialization (CPDC) are pleased to announce a strategic initiative  to support the development of next-generation radiopharmaceuticals in Canada. This collaboration represents a unique opportunity to align Canada’s strengths and global expertise in this expanding field. Together we are initiating a collective effort that will foster innovation and growth, and we … Read more

Vancouver, B.C. – December 17, 2024 – The inaugural Symposium on Medical Isotopes, hosted by the Canadian Medical Isotope Ecosystem (CMIE) in partnership with the Canadian Nuclear Isotope Council (CNIC), took place on December 12-13, 2024, at the Holiday Inn & Suites in Vancouver. The event attracted over 70 key stakeholders from across Canada’s medical isotope … Read more

Celebrating our Contribution to Advancing Nuclear Medicine for the World HAMILTON, ON, March 19, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development and commercialization of radiopharmaceuticals, is proud to celebrate its 16th anniversary today. Since 2008, CPDC has been at the forefront of advancing nuclear medicine for … Read more

Significant Milestone on the Path to Submission for Canadian Regulatory Approval in Late 2024 HAMILTON, ON, March 13, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development and commercialization of radiopharmaceuticals, today announced the closure of the Canadian Phase 3 trial for [18F]PSMA-1007. [18F]PSMA-1007 is a positron-emitting tomography … Read more

HAMILTON, ON, July 29, 2024 – The Centre for Probe Development and Commercialization (CPDC), a global leader in radiopharmaceutical development and commercialization, today announced that its Founder, John Valliant, Ph.D., has stepped down from its Board of Directors. Dr. Valliant established CPDC in 2008 as a Centre of Excellence for the Commercialization of Research in … Read more

HAMILTON, ON and TORONTO, ON, July 6, 2023 – The Centre for Probe Development and Commercialization (CPDC) is pleased to announce a collaboration with Dr. Neil Vasdev at the Centre for Addiction and Mental Health (CAMH) to develop a novel positron emission tomography (PET) tracer specific for the activin receptor-like kinase 2 (ALK2) protein. Under … Read more

HAMILTON, ON and VANCOUVER, BC, July 4, 2023 – The Centre for Probe Development and Commercialization (CPDC) is proud to announce its funding of a new research project led by Dr. Robert Britton at Simon Fraser University (SFU) aimed at developing a novel positron emission tomography (PET) tracer that targets the L-type amino acid transporter … Read more